prepared you, of our call. Thank today's several everyone update In our I'll on business. you joining aspects remarks,
quarter our second and the in performance highlight activities. record PacBio's commercial discuss I'll First,
Revio quarter Second, performance I'll comment its on and customer since launch. update full field in first
was I'll share of beginning are us of us, announced at will the finally priorities Biosystems, executing set And at and through financials our XXXX against detail. more guidance of how which launch and with year. acquisition I the year Apton highlight we Onso and take the behind the then in I'll Next, commercial today our earlier recent our close a forth half Susan
to quarter of with performance, to as for second PacBio XX% Starting drove record revenue in rapid our for by history quarterly in manufacturing year the quarter first compared Systems we we installations XX for XX excellent another posting team $XX of QX revenue June XX. as record installed did grew of revenue region and ship with the the adoption enabled and an of Revio each last million brought scaling time exceeded to Revios job which ramping The us our revenue. and base Revio
healthy demand have a revenue our quarter momentum $XXX million year confidence XX% over to We with increased to our Revio's and instruments. exited XX% XXXX. growth revenue our to we for ability Additionally, full expectations $XXX further and between XXXX. backlog of be now Revio representing to customer million, the expect meet raise
to have their interest customers now XXX of bundles customers set we commitment to received Onso new date, demonstrated Revio, orders, multi several and diverse including approximately A system different Revio customers. orders from steady from and have
sequencing several link accuracy, HiFi on to structural emphasis fact, States projects, and In a throughput aim now on previously to IIb decided XX% customers. from on ordered and alternative long in human an platform. to research decided used Requiring to They university that to and included an technology quarter had second PacBio with customer invest constraints new the the disease. due the scale, in landscape the read came instruments Revio. variation of Sequel about the These leverage the to in Southeast reproducibility re-examine United its
in customer to read targeted long short used New also the consolidate workflows genes first streamlined and to The which into utilizing it customers approach sequencing. panels Innsbruck, multi and difficult which PCR quarter HiFi Sanger sequencing of included analyze the in Medical sequencing, included read plans Revio University the marks Austria.
ordered to as and the metagenomics suited match appropriate They New long-reads Revio, The approach academic human They Onso in the hospitals to best health. customer The leverage Indonesia binding Foundation. sequencing with included orders with plan also the targeted order promote the repository diverse plans the and difficult the Group to liquid to research on collaborates biopsy. panels genomic sequencing in and instrument sequencing improve country targeted applications first from bundle sequencing Onso institutions to YSDF develop across accuracy in in build quarter genes. as whole genomic genome a by well customer use Indonesian to for to the sequence across the application. of population, the
samples quarter sequencing population service in to by leading program Revio's the increased continue New throughput, provider genetics a the start its into population Jersey, genomic Revio of detection Veteran a expects large scale a sequencing and Sample, expand funded of biorepository accuracy and first programs. received to direct Department methylation and genomics second In long-read for the Affairs. based cohort
is second HiFi an long-read milestone in released exactly entering program the the the as genomes. interest public effect can PacBio research talking genomes, adoption. type And about quarter the XXXX we've and long-read research over data more can of been in from important flywheel [indiscernible] realm unlock prompting data more accelerate discoveries, This that
total Revio's in and to Revio from product a our some in with quarter up and strong of higher in larger launch. usage during $X consumables is projects the customers utilization indicate strength come. This performance early utilization anticipation consumables from Customers anticipated second revenue the start the of working approximately quarter. to of million inventory customers million attributable Customer field building a to ramping $XX.X their are Revio
see during to quarter. a flow consumables encouraging Revio also was customers also demonstrates This busy the of to place that continual customers larger come. keep orders for quarters standing samples to anticipate their It
next Revio early of represented customers. I As positive, we a the first year. that though reminder, wave pull-through understand are our sometime utilization and and will better ordering Revio trends, expect normalized
field further add continues system performance, customers to approximately failure launch Regarding per our are improve Later below that performance. average, hit and sequencing more functionality cell. Gigabases The SMRT year, to that specification and of is rate updates and targets. anticipate this up libraries XX we improve on KB launching continue heart our will well XX
Overall Revio proving be is reliable in the field. to
customers that, Maryland University up instrument began noted one detection Revio scientific that de see to Revio, powered. across this Washington sequencing and SMRT publications assemblies. researchers variation, on exciting SMRT of As coverage, the also has novo genome first found They in system WGS can cell". generate PacBio from consistent XXx and on their "highly and new cells of and the Revio ramp sequencing consistency and preprint, on In University long-read of methylation, wave accurate, coverage the is it's one
with In researchers XX of provide that of greatly International a preprint, control group plant species of Consortium, effective analysis reduce they weed methods sustainable goals described yields. another the to developing and the the that from can reported environmental threats enabling crop about Weed and genomic insights XX pan sequencing Revio, how this and with institutions,
only from calling SMRT instead of All that II a II but to and HiFi study Revio cells. demonstrated Sequel example, variant identical Revio three assemblies benchmark the third sequencing SMRT a one were cell As datasets, required Us Sequel data, Consortium essentially by of
Additionally, the lower nanopore resulted nanopore the and with data, nanopore a observed certain PacBio that in reports, error data and they compared study than precision rate nanopore HiFi Consistent classes higher methods. indel with data much data. that HiFi latest standard calling in variant had previous compared duplex to
but to delighting its also score our survey and of offer completed am and to service continuing resulting to best-in-class pleased around and that, throughput pleased to customer quality of quarter With demonstrates forward that Net with the final economics, PacBio that provides. our all Promoter in our a only was look are not with changing globe. customers our the game XX. customers the in annual Customers we Revio This I of support commitment
today early core accuracy. to SBB of we of by is than The long-read years at the two ago from gears which first the from with stage system promise we Onso the of binding commercial Switching level delivering an I'm our sequencing extraordinary excited system. earlier the announce technology customers to was chemistry acquired shipped that short-read, Onso less or Omniome sequencing
offer six to of both highly our I bases, sequencer every for in deliver specification offer to monumental team company long PacBio plus short-read solutions We moment omni less advertises. than this for error believe and that technology to the second becoming in designed only Bio XX% differentiated in next or into ecosystem. journey other platform our sequencing it a multi multiplatform, sequencing customer months. strategic across for a developing congratulate is specifically accuracy we aims designed the company that bases the and sequencer levels one systems at truly This launched Packed QXX sequencing marks it's a genomics as XX,XXX to as at step believe a currently the entire positions of PacBio no
of range first or ultralow disease detect accurately complexity collaborator variance including the Translational Institute that One the high biopsy. Onso systems applications TGen, found the ability going without error Genomics a Research who an for to the early SBB correction in of liquid is broad infectious and to demonstrated need
commercially, the we manufacturing plan that XXXX. scale are Now we shipping to throughout second-half of
related PacBio's Additionally, the milestone the and instrument particularly The and month. to address sequencing and this short-read associated rare Onso consumables PacBio of the of once Omniome installation is complete portion this will acquisition of instrument be both consumables very expects later to are expected related triggered researchers Onso understand payment looking a find been ship with to variants. shipped. have significant market, where Onso
believe Therefore, a high As discoveries sequencing mid short-read to both our our we throughput, made, to develop a platform. highly with then will that chemistry. platforms these throughput want based these SBB which experiments portfolio is researchers on and accurate scale will high require their strategy multiproduct are short-read
share past of Bay that Apton image a few announced chemistry, to working found result to system. developing sequencing today our processing. throughput acquire Area sequencer and pleased is a of state-of-the-art for that SBB platform using a we a company that months, optics capable Biosystems, the with data Apton in an In high generating based Apton's short-read clustering, strategy, throughput we quality As sequencing agreement high earlier on into I'm entered we
flow company, throughput of launched differentiated As while expect differentiated When deliver high a further we per billions on economics. and we sequencing extraordinary advanced with and a sequencer. and reads to to offerings, Apton's high combined SBB with other technologies platform of this optimize par to output throughput cell optics develop accuracy accuracy chemistry expect integrate the compelling imaging providing
high throughput and density a throughput Apton development. launching and is of Increasing the a will give in development that us one key head sequencer start significant challenges in
and the engineers this Apton's planning started over from lean and bringing are several have next organization We sequencer. already development generation of talented scientists
of is will our high acquisition many course, likely a Of and how PacBio operating our throughput our keeping going forward. be R&D may not a growth annual map this range sequencer expenses the develop targets we you reduce compound and of on this development wondering sequencer impact OpEx under deviate throughput XXXX, product to always will target. through has to our road high and short-read acquisition been Developing accelerate our that remain overall to long from expenses system. the X% while Therefore, committed is to required expected acquisition on delivering
we fact, discuss operating previously than anticipated that shortly expect will In expenses Susan be in to XXXX. lower
with that, call to pass discuss to I'll over our And the Susan? financials. Susan